BOSTON — Organogenesis Holdings Inc. has signed a full-building lease at 100 Technology Way in Smithfield, Rhode Island, a 123,000-square-foot biomanufacturing facility owned by The Davis Companies. The facility will serve as a key site for Organogenesis’ growing production needs in regenerative medicine and advanced wound care.
The lease marks a significant expansion for Organogenesis, which plans to use the facility to scale its biomanufacturing capabilities while reinforcing its long-term commitment to New England.
“In a competitive manufacturing and life sciences market, this agreement underscores Davis’ focus on supporting innovative companies with premier facilities in strategic locations,” said Jon Needham, Senior Vice President of Asset Management at Davis. “We’re excited to welcome Organogenesis and play a role in their continued growth.”
The property is currently undergoing a multi-year transformation into a state-of-the-art cGMP (Current Good Manufacturing Practice) facility, complete with advanced utility infrastructure tailored for complex biomanufacturing demands.
Conveniently located near Interstate 295, the site offers direct access to Cambridge and Boston, placing it within one of the nation’s most dynamic life sciences corridors.
The lease was brokered by Robert Coughlin and Bobby Jangro of JLL, representing Organogenesis, and Mark Winters and Tyler McGrail of Newmark, representing Davis.
This expansion highlights the ongoing growth of New England’s life sciences sector and the increasing demand for specialized manufacturing space across the region.
